Presentation to feature results from first clinical study of ART26.12 and highlight the potential of

Oncotelic's AI drug discovery platform invites scientists, developers and biotech founders to connec

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and r

Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and r

Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight a

Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analys

Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family

Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and t

TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HI

https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-

RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and

U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weig

Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the anal

Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral

Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. T

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the anal

Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest f

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raise

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weig

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analys

Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025.

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnin

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fisc

  During Friday, 125 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly

  On Thursday, 1076 companies hit new 52-week lows.

  On Monday, 429 stocks made new 52-week lows.

  During Friday's session, 574 stocks hit new 52-week lows.

  Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings fo

  During Wednesday's trading, 435 companies set new 52-week lows.